Predict your next investment

Corporation
HEALTHCARE | Drug Manufacturing / Generics
sawai.co.jp

See what CB Insights has to offer

Investments

2

Portfolio Exits

1

Partners & Customers

2

About Sawai Pharmaceutical

Sawai Pharmaceutical (TYO: 4555) is a Japanese generic pharmaceuticals manufacturer. Sawai focuses on the manufacturing and sales, export and import of generic pharmaceutical products.

Sawai Pharmaceutical Headquarter Location

5-2-30 Miyahara, Yodogawa-ku

Osaka, 532-0003,

Japan

+81 06-6105-5711

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Latest Sawai Pharmaceutical News

BRIEF—Tokyo court upholds Chugai Edirol patent

Feb 24, 2022

The Tokyo District Court today rendered judgment to deny the plaintiff’s claim in the lawsuit filed on February 17, 2021 regarding the generic drugs to an osteoporosis agent, active vitamin D3 derivative Edirol Capsule (eldecalcitol) based on the patent owned by Japanese pharma major Chugai Pharmaceuticals against Sawai Pharmaceutical, Nichi-Iko Pharmaceutical and Nissan Chemical. On February 17, 2020, Sawai and Nichi-Iko obtained approval from the Ministry of Health, Labor and Welfare for their generic version of Edirol Capsule, respectively. Chugai recognizes that Sawai and Nichi-Iko have outsourced the manufacturing of the active pharmaceutical ingredient (API) to Nissan Chemical, purchased the API from Nissan Chemical, and used it to manufacture and sell their generic drugs. The above three companies have been producing and using the crystalline form covered by the patent owned by Chugai in these processes. Therefore, Chugai filed a patent infringement lawsuit with the Tokyo District Court, based on the patent No 3429432 owned by Chugai, demanding the suspension of production and use and disposal of the substance in crystalline form, for which Chugai holds the patent, in association with the generic drug, and also demanding damage compensation against Sawai, Nichi-Iko and Nissan Chemical. The Tokyo District Court has rendered judgment to deny the plaintiff’s claim in the lawsuit today.

Sawai Pharmaceutical Investments

2 Investments

Sawai Pharmaceutical has made 2 investments. Their latest investment was in SUSMED as part of their Series B on September 9, 2020.

CBI Logo

Sawai Pharmaceutical Investments Activity

investments chart

Date

Round

Company

Amount

New?

Co-Investors

Sources

9/24/2020

Series B

SUSMED

$0.47M

Yes

2

12/28/2006

Corporate Minority - II

Subscribe to see more

Subscribe to see more

10

Date

9/24/2020

12/28/2006

Round

Series B

Corporate Minority - II

Company

SUSMED

Subscribe to see more

Amount

$0.47M

New?

Yes

Subscribe to see more

Co-Investors

Sources

2

10

Sawai Pharmaceutical Portfolio Exits

1 Portfolio Exit

Sawai Pharmaceutical has 1 portfolio exit. Their latest portfolio exit was SUSMED on December 24, 2021.

Date

Exit

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Acquirer

Sources

12/24/2021

IPO

$99M

Public

1

Date

12/24/2021

Exit

IPO

Companies

Valuation

$99M

Acquirer

Public

Sources

1

Sawai Pharmaceutical Acquisitions

1 Acquisition

Sawai Pharmaceutical acquired 1 company. Their latest acquisition was Upsher-Smith Laboratories - Generics Business on April 20, 2017.

Date

Investment Stage

Companies

Valuation
Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model.

Total Funding

Note

Sources

4/20/2017

$99M

Acquired Unit

3

Date

4/20/2017

Investment Stage

Companies

Valuation

$99M

Total Funding

Note

Acquired Unit

Sources

3

Sawai Pharmaceutical Partners & Customers

2 Partners and customers

Sawai Pharmaceutical has 2 strategic partners and customers. Sawai Pharmaceutical recently partnered with Neurolief on January 1, 2021.

Date

Type

Business Partner

Country

News Snippet

Sources

1/28/2021

Licensor

Israel

Neurolief and Sawai Enter into Exclusive Development and Marketing Agreement for Relivion®

TAMPA , Fla. -- -- Neurolief Ltd. , a neurotechnology innovator , today announces that it has entered into an exclusive agreement with Sawai Pharmaceutical Co. , Ltd. for the development and marketing of Relivion , a non-invasive digital medical device for migraine and depression , in Japan .

2

10/30/2017

Licensor

United Kingdom

Subscribe to see more

Subscribe to see more

10

Date

1/28/2021

10/30/2017

Type

Licensor

Licensor

Business Partner

Country

Israel

United Kingdom

News Snippet

Neurolief and Sawai Enter into Exclusive Development and Marketing Agreement for Relivion®

TAMPA , Fla. -- -- Neurolief Ltd. , a neurotechnology innovator , today announces that it has entered into an exclusive agreement with Sawai Pharmaceutical Co. , Ltd. for the development and marketing of Relivion , a non-invasive digital medical device for migraine and depression , in Japan .

Subscribe to see more

Subscribe to see more

Sources

2

10

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.